ClinicalTrials.gg
Not yet recruitingNCT07166354Updated Nov 2, 2026

Clinical Study of mTOR Inhibitor as a Treatment for Grey Hair (Canities)

A Phase 1/2 interventional study of CS-002 and Placebo Topical Solution in Canities and Grey Hair, sponsored by Applied Biology, Inc.. Not yet recruiting. Open to participants aged 30 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Applied Biology, Inc. · Phase 1/2, Interventional, and Treatment

Updated Nov 2, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
30 Years to 65 Years
Sex
All
01

Study summary

Clinical Study to Assess the Safety and Efficacy of CS-002 (mTOR inhibitor) as a treatment for Canities (Grey Hair)

Read the detailed description

CS-002 is a small molecule that is an mTOR ("mammalian target of rapamycin ") inhibitor. In vitro and a small pilot study demonstrated re-pigmentation of grey hair following CS-002 application. The aim of this study is to assess the safety and efficacy of CS-002 as a treatment for grey hair.

02

Conditions studied

  • Canities
  • Grey Hair
03

In context

Lead sponsor

Applied Biology, Inc. is the lead sponsor of 25 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 30 to 65
  • Diagnosed with Grey Hair (Canities)
  • Willing and able to apply the treatment as directed, comply with study
  • Otherwise healthy
  • Able to give

Exclusion criteria

Exclusion Criteria:

  • A medical history that may interfere with study objectives
  • Women who are pregnant, lactating, or planning to become pregnant during the study period
  • Subjects who have experienced a medical event within 90 days of the visit (e.g., stroke, myocardial infarction, etc)
  • Subjects who have known allergies to any in CS-001
  • Subjects who are currently participating in another clinical study or have completed another clinical study with an drug or device in the treatment area within 30 days prior to study treatment initiation
  • Subjects who have used any topical prescription medications in the treatment area within 30 days prior to study treatment initiation
  • Subjects who have had a dermatological procedure such as surgery in the treatment area within 30 days prior to study treatment initiation
  • Subject is unable to provide consent or make the allotted clinical visits
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    CS-002

    CS-002 Topical Treatment

    Drug: CS-002

  • Placebo comparator
    Placebo

    Placebo Topical Treatment

    Drug: Placebo Topical Solution

Interventions

  • DrugCS-002

    CS-002 Topical Treatment

  • DrugPlacebo Topical Solution

    Placebo Topical Solution

06

What researchers measure

Primary outcomes

  1. Greying Severity Score

    Greying Severity Score (GSS). Mild Greying score between 0-5, Moderate Greying score between 6-10 and Severe Greying score between 11-15

    Time frame: Week [0,24]

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Singal A, Daulatabad D, Grover C. Graying severity score: A useful tool for evaluation of premature canities. Indian Dermatol Online J. 2016 May-Jun;7(3):164-7. doi: 10.4103/2229-5178.182372. PubMed 27294049 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Jun 2027; primary completion for Oct 2027, 4 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: start Oct 2025 → Jun 2027, primary completion Jun 2027 → Oct 2027 and completion Sep 2027 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2025
First posted
Sep 10, 2025
StartEst.
Jun 1, 2027was Oct 2025
Primary completionEst.
Oct 15, 2027was Jun 2027
CompletionEst.
Dec 15, 2027was Sep 2027
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 1, 2025→Jun 1, 2027
Nov 2, 2026
Primary completion
Jun 15, 2027→Oct 15, 2027
Nov 2, 2026
Study completion
Sep 15, 2027→Dec 15, 2027
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Start date Oct 1, 2025→Jun 1, 2027
    Primary completion Jun 15, 2027→Oct 15, 2027
    Study completion Sep 15, 2027→Dec 15, 2027
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07166354
Collaborators
Complex Science
Responsible party
Sponsor
First posted
Sep 10, 2025
Start date
Jun 1, 2027 (estimated)
Primary completion
Oct 15, 2027 (estimated)
Completion
Dec 15, 2027 (estimated)
Last update
Nov 2, 2026

Study contacts

Andy Goren, MD
Contact
clincalstudies@appliedbiology.com
6507040850

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion